Periprocedural effects of statins on the incidence of contrast-induced acute kidney injury: A systematic review and trial sequential analysis

International Journal of Cardiology

Volumn 206, Issue , 2016, Pages 143-152

  Wang, Nelson ^a   Qian, Pierre ^b   Yan, Tristan D ^a   Phan, Kevin ^a,b  

^a MACQUARIE UNIVERSITY   (Australia)

^b WESTMEAD HOSPITAL   (Australia)

Author keywords

Acute kidney injury; Angioplasty; Contrast; Meta analysis; Percutaneous coronary intervention; Trial sequential analysis

Indexed keywords

ATORVASTATIN; BICARBONATE; CYSTATIN C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IODIXANOL; IOHEXOL; IOPAMIDOL; IOPROMIDE; IOVERSOL; PLACEBO; ROSUVASTATIN; SIMVASTATIN; CONTRAST MEDIUM;

ANGIOCARDIOGRAPHY; CLINICAL PROTOCOL; COHORT ANALYSIS; CONTRAST INDUCED NEPHROPATHY; CREATININE CLEARANCE; DISEASE SEVERITY; DRUG ACTIVITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; GLOMERULUS FILTRATION RATE; HUMAN; HYDRATION; INCIDENCE; LOW DRUG DOSE; META ANALYSIS; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RENAL PROTECTION; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SYSTEMATIC REVIEW; ACUTE KIDNEY INJURY; ADVERSE EFFECTS; CHEMICALLY INDUCED; CORONARY ANGIOGRAPHY; DOSE RESPONSE; DRUG EFFECTS; PERIOPERATIVE PERIOD; PHYSIOLOGY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ACUTE KIDNEY INJURY; CONTRAST MEDIA; CORONARY ANGIOGRAPHY; DOSE-RESPONSE RELATIONSHIP, DRUG; GLOMERULAR FILTRATION RATE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; PERCUTANEOUS CORONARY INTERVENTION; PERIOPERATIVE PERIOD; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84959354825     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2016.01.004     Document Type: Article

References (36)

1. P.A. McCullough contrast-induced acute kidney injury J. Am. Coll. Cardiol. 51 2008 1419 1428
2. S.D. Weisbord, and P.M. Palevsky Contrast-induced acute kidney injury: short- and long-term implications Semin. Nephrol. 31 2011 300 309
3. A.C.T. Investigators Acetylcysteine for prevention of renal outcomes in patients undergoing coronary and peripheral vascular angiography: main results from the randomized acetylcysteine for contrast-induced nephropathy trial (ACT) Circulation 124 2011 1250 1259
4. S.S. Brar, S. Hiremath, G. Dangas, R. Mehran, S.K. Brar, and M.B. Leon Sodium bicarbonate for the prevention of contrast induced-acute kidney injury: a systematic review and meta-analysis Clin. J. Am. Soc. Nephrol. 4 2009 1584 1592
5. F. Stacul, A. Adam, C.R. Becker, C. Davidson, N. Lameire, P.A. McCullough, and et al. Strategies to reduce the risk of contrast-induced nephropathy Am. J. Cardiol. 98 2006 59 77
6. W. Wijns, P. Kolh, N. Danchin, C. Di Mario, V. Falk, T. Folliguet, and et al. Guidelines on Myocardial Revascularization 2010
7. P. Kolh, S. Windecker, F. Alfonso, J.P. Collet, J. Cremer, V. Falk, and et al. ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) Eur. J. Cardiothorac. Surg.: Off. J. Eur. Assoc. Cardiothorac. Surg. 46 2014 517 592 2014
8. A.W. Chan, D.L. Bhatt, D.P. Chew, M.J. Quinn, D.J. Moliterno, E.J. Topol, and et al. Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention Circulation 105 2002 691 696
9. E. Seeliger, M. Sendeski, C.S. Rihal, and P.B. Persson Contrast-induced kidney injury: mechanisms, risk factors, and prevention 2012
10. S. Windecker, P. Kolh, F. Alfonso, J.P. Collet, J. Cremer, V. Falk, and et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) Eur. Heart J. 35 2014 2541 2619
11. J. Wetterslev, K. Thorlund, J. Brok, and C. Gluud Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis J. Clin. Epidemiol. 61 2008 64 75
12. R.M. Turner, S.M. Bird, and J.P. Higgins The impact of study size on meta-analyses: examination of underpowered studies in Cochrane reviews PLoS One 8 2013 e59202
13. D. Moher, A. Liberati, J. Tetzlaff, and D.G. Altman Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement Int. J. Surg. 8 2010 336 341 (London, England)
14. K. Phan, D.H. Tian, C. Cao, D. Black, and T.D. Yan Systematic review and meta-analysis: techniques and a guide for the academic surgeon Ann. J. Cardiothorac. Surg. 4 2015 112 122
15. O. Abaci, A. Arat Ozkan, C. Kocas, G. Cetinkal, O. Sukru Karaca, O. Baydar, and et al. Impact of Rosuvastatin on contrast-induced acute kidney injury in patients at high risk for nephropathy undergoing elective angiography Am. J. Cardiol. 115 2015 867 871
16. S. Acikel, H. Muderrisoglu, A. Yildirir, A. Aydinalp, E. Sade, N. Bayraktar, and et al. Prevention of contrast-induced impairment of renal function by short-term or long-term statin therapy in patients undergoing elective coronary angiography Blood Coagul. Fibrinolysis int. j. Haemost. Thromb. 21 2010 750 757
17. S. Cao, P. Wang, K. Cui, L. Zhang, and Y. Hou [Atorvastatin prevents contrast agent-induced renal injury in patients undergoing coronary angiography by inhibiting oxidative stress]. Nan fang yi ke da xue xue bao J. Southern Med. Univ. 32 2012 1600 1602
18. Y. Han, G. Zhu, L. Han, F. Hou, W. Huang, H. Liu, and et al. Short-term rosuvastatin therapy for prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease J. Am. Coll. Cardiol. 63 2014 62 70
19. S.H. Jo, B.K. Koo, J.S. Park, H.J. Kang, Y.S. Cho, Y.J. Kim, and et al. Prevention of radiocontrast medium-induced nephropathy using short-term high-dose simvastatin in patients with renal insufficiency undergoing coronary angiography (PROMISS) trial - a randomized controlled study Am. Heart J. 155 499 2008 e1 e8
20. M. Leoncini, A. Toso, M. Maioli, F. Tropeano, S. Villani, and F. Bellandi Early high-dose rosuvastatin for contrast-induced nephropathy prevention in acute coronary syndrome: results from the PRATO-ACS Study (Protective Effect of Rosuvastatin and Antiplatelet Therapy On contrast-induced acute kidney injury and myocardial damage in patients with Acute Coronary Syndrome) J. Am. Coll. Cardiol. 63 2014 71 79
21. W. Li, X. Fu, Y. Wang, X. Li, Z. Yang, X. Wang, and et al. Beneficial effects of high-dose atorvastatin pretreatment on renal function in patients with acute ST-segment elevation myocardial infarction undergoing emergency percutaneous coronary intervention Cardiology 122 2012 195 202
22. H. Ozhan, I. Erden, S. Ordu, M. Aydin, O. Caglar, C. Basar, and et al. Efficacy of short-term high-dose atorvastatin for prevention of contrast-induced nephropathy in patients undergoing coronary angiography Angiology 61 2010 711 714
23. G. Patti, E. Ricottini, A. Nusca, G. Colonna, V. Pasceri, A. D'Ambrosio, and et al. Short-term, high-dose Atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN [atorvastatin for reduction of myocardial damage during angioplasty-contrast-induced nephropathy] trial Am. J. Cardiol. 108 2011 1 7
24. C. Quintavalle, D. Fiore, F. De Micco, G. Visconti, A. Focaccio, B. Golia, and et al. Impact of a high loading dose of atorvastatin on contrast-induced acute kidney injury Circulation 126 2012 3008 3016
25. A. Toso, M. Maioli, M. Leoncini, M. Gallopin, D. Tedeschi, C. Micheletti, and et al. Usefulness of atorvastatin (80 mg) in prevention of contrast-induced nephropathy in patients with chronic renal disease Am. J. Cardiol. 105 2010 288 292
26. H. Xian-ping, W. Rui-xia, Y. Yong, C. Zheng, and C. Bin Prevention of contrast-induced nephropathy using high-dose atorvastatin in patients with coronary heart disease undergoing elective percutaneous coronary intervention Milit Med. J. South China 24 2010 448 451 (in Chinese)
27. J. Xinwei, F. Xianghua, Z. Jing, G. Xinshun, X. Ling, F. Weize, and et al. Comparison of usefulness of simvastatin 20 mg versus 80 mg in preventing contrast-induced nephropathy in patients with acute coronary syndrome undergoing percutaneous coronary intervention Am. J. Cardiol. 104 2009 519 524
28. X. Zhou, Y.Z. Jin, Q. Wang, R. Min, and Z. XY. [Efficacy of high dose atorvastatin on preventing contrast induced nephropathy in patients underwent coronary angiography] Zhonghua Xin Xue Guan Bing Za Zhi 37 2009 394 396
29. T. Senoo, M. Motohiro, H. Kamihata, S. Yamamoto, T. Isono, K. Manabe, and et al. Contrast-induced nephropathy in patients undergoing emergency percutaneous coronary intervention for acute coronary syndrome Am. J. Cardiol. 105 2010 624 628
30. B.-C. Zhang, W.-M. Li, and Y.-W. Xu High-dose statin pretreatment for the prevention of contrast-induced nephropathy: a meta-analysis Can. J. Cardiol. 27 2011 851 858
31. T. Zhang, L.H. Shen, L.H. Hu, and B. He Statins for the prevention of contrast-induced nephropathy: a systematic review and meta-analysis Am. J. Nephrol. 33 2011 344 351
32. J. Brok, K. Thorlund, J. Wetterslev, and C. Gluud Apparently conclusive meta-analyses may be inconclusive - trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses Int. J. Epidemiol. 38 2009 287 298
33. S. Bangalore, S. Kumar, J. Wetterslev, and F.H. Messerli Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential analyses of 147,020 patients from randomised trials BMJ 342 2011 d2234 (Clinical research ed)
34. Y. Li, Y. Liu, L. Fu, C. Mei, and B. Dai Efficacy of short-term high-dose statin in preventing contrast-induced nephropathy: a meta-analysis of seven randomized controlled trials PLoS One 7 2012 e34450
35. G. Marenzi, G. Lauri, E. Assanelli, J. Campodonico, M. De Metrio, I. Marana, and et al. Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction J. Am. Coll. Cardiol. 44 2004 1780 1785
36. S.L. Chen, J. Zhang, F. Yei, Z. Zhu, Z. Liu, S. Lin, and et al. Clinical outcomes of contrast-induced nephropathy in patients undergoing percutaneous coronary intervention: a prospective, multicenter, randomized study to analyze the effect of hydration and acetylcysteine Int. J. Cardiol. 126 2008 407 413